New hope for pancreatic cancer: targeted pill plus chemo tested
NCT ID NCT07026279
First seen Oct 31, 2025 · Last updated May 22, 2026 · Updated 27 times
Summary
This study tests a new daily pill (narmafotinib) combined with standard chemotherapy (FOLFIRINOX) in about 67 people with pancreatic cancer that has spread. The goal is to find the safest and most effective dose. This is not a cure, but aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Epworth Healthcare
Richmond, Victoria, 3121, Australia
-
GenesisCare
St Leonards, New South Wales, 2065, Australia
Conditions
Explore the condition pages connected to this study.